FierceBiotech

Gilead's Aztreonam for Inhalation Solution to be Reviewed by FDA Anti-Infective Drugs Advisory Committee on December 10, 2009

Gilead's Aztreonam for Inhalation Solution to be Reviewed by FDA Anti-Infective Drugs Advisory Committee on December 10, 2009 FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) ...
FierceBiotech

Press Release; Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine

Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis Data Presented at Cystic Fibrosis Therapeutics Development Network ...
Medscape

Aztreonam Lysine for Inhalation

Purpose The pharmacology, safety, efficacy, pharmacokinetics, pharmacodynamics, current place in therapy, and potential future therapeutic uses of inhaled aztreonam are reviewed. Conclusion Inhaled ...
Reuters

Gilead Sciences announces achievement of primary efficacy endpoint in 2nd Phase III Study of Aztreonam Lysine for inhalation

Co announced that its Phase III AIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation for the treatment of people with cystic fibrosis who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) ...
Medscape

Aztreonam Lysine for Inhalation

Am J Health Syst Pharm. 2012;69(2):107-115. Kristen Zeitler, Pharm.D., is Postgraduate Year 1 Pharmacy Practice Resident, Hospital of the University of Pennsylvania, Philadelphia; at the time of ...